Cancer Genetics, Inc. Partners With Leading Southwest Gynecological Pathology Lab To Provide Great Availability Of FHACT(R), A Non-Invasive, Genomic Test To Guide The Detection And Management Of Cervical Cancer

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

RUTHERFORD, N.J., June 3, 2014 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) a DNA-based diagnostics company focused on developing genomic-based oncology tests and services, announced today that it has entered into a multi-year agreement to collaborate and provide PathAdvantage Associated with Cancer Genetics' proprietary FHACT®, a FISH-based genomic test for the detection and management of cervical cancer.

Help employers find you! Check out all the jobs and post your resume.

Back to news